Targeting the CaN/FoxO1/FABP4 Pathway: Novel Insights into Atherosclerosis Progression

Study Background and Research Question

Atherosclerosis, a progressive disorder characterized by arterial plaque buildup, remains a leading cause of cardiovascular morbidity and mortality. The disease is driven by complex interactions among lipid metabolism, inflammation, and vascular dysfunction. Foam cell formation—driven by lipid-laden macrophages—is central to plaque development and progression. Recent attention has focused on the molecular mechanisms linking endoplasmic reticulum (ER) stress, intracellular calcium handling, and lipid accumulation in macrophages. The sarcoplasmic/endoplasmic reticulum Ca²⁺ ATPase 2 (SERCA2) enzyme, crucial for maintaining ER Ca²⁺ homeostasis, is increasingly recognized as a regulator of these processes. However, how SERCA2 dysfunction contributes to atherogenesis through downstream signaling remains incompletely understood. The current study addresses this gap by examining the molecular consequences of a specific SERCA2 mutation and the potential for targeted pharmacological intervention (Tong et al., 2025).

Key Innovation from the Reference Study

The central innovation of this research lies in elucidating a mechanistic pathway in which SERCA2 dysfunction in macrophages triggers a cascade—specifically, the calcineurin (CaN)/forkhead box O1 (FoxO1)/fatty acid binding protein 4 (FABP4) axis—that promotes aberrant lipid metabolism and foam cell formation. By employing a genetic mouse model carrying the C674S SERCA2 mutation, the study reveals that impaired SERCA2 activity leads to upregulation of calcineurin, which in turn enhances FoxO1 nuclear translocation and increases FABP4 expression. This molecular sequence results in heightened fatty acid synthesis and accumulation within macrophages, ultimately driving foam cell and plaque formation. Importantly, pharmacological inhibition of FABP4 is shown to disrupt this pathological sequence, mitigating both foam cell formation and atherosclerotic lesion development. This direct mechanistic link between SERCA2 dysfunction and the CaN/FoxO1/FABP4 pathway is newly defined in this study, establishing FABP4 as a critical mediator and therapeutic target in atherosclerosis progression.

Methods and Experimental Design Insights

The investigators utilized a heterozygous knock-in mouse model harboring the C674S mutation in SERCA2 (designated SKI mice), which models SERCA2 dysfunction under conditions relevant to atherosclerosis. Serum from SKI and wild-type littermates underwent metabolomic profiling to assess systemic lipid alterations. The aorta and aortic root were harvested for histological and immunohistochemical analysis to quantify plaque burden and foam cell content. For mechanistic studies, bone marrow-derived macrophages (BMDMs) from SKI mice were isolated and subjected to protein expression assays, lipid uptake/accumulation measurements, and pathway-specific interventions using pharmacological inhibitors and genetic knockdown.

Key experimental approaches included:

• Assessment of SERCA2 activity via functional assays in BMDMs.
• Immunoblotting and immunofluorescence to quantify CaN, FoxO1, and FABP4 levels and subcellular localization.
• Use of established pharmacological tools: cyclosporine (CsA) as a calcineurin inhibitor, AS1842856 as a FoxO1 inhibitor, and BMS 309403 as a selective FABP4 inhibitor.
• Evaluation of lipid metabolic enzymes (e.g., ACAT2, FAS) and cholesterol transporters (ABCA1/G1) by qPCR and Western blotting.
• Functional readouts including foam cell formation (oil red O staining), cholesterol ester content, and inflammatory cytokine secretion.

Core Findings and Why They Matter

The study's principal observations are as follows:

• SERCA2 Dysfunction Promotes Atherogenesis: Mice carrying the C674S SERCA2 mutation developed more pronounced atherosclerotic lesions and exhibited increased foam cell content relative to wild-type controls.
• Activation of the CaN/FoxO1/FABP4 Pathway: SERCA2 deficiency in BMDMs led to increased calcineurin activity, nuclear localization of FoxO1, and upregulation of FABP4. These changes were associated with enhanced fatty acid synthesis, cholesterol esterification, and lipid droplet formation.
• Pharmacological Inhibition Reverses Pathology: Targeted inhibition at multiple nodes—using CsA (calcineurin inhibitor), AS1842856 (FoxO1 inhibitor), or BMS 309403 (FABP4 inhibitor)—attenuated foam cell formation and reduced atherosclerotic lesion area in vivo. Notably, partial genetic deficiency of FABP4 also recapitulated the protective effects.
• FABP4 as a Central Effector: These findings underscore FABP4's pivotal role downstream of SERCA2 and FoxO1 in mediating lipid metabolic dysregulation and macrophage foam cell formation, establishing it as a key target for therapeutic intervention (Tong et al., 2025).

This mechanistic clarity not only highlights SERCA2’s importance in vascular health but also positions FABP4 as a modifiable node in atherosclerosis and potentially other metabolic diseases. Inhibition of FABP4 thus represents a rational, pathway-specific approach to ameliorate disease progression.

Comparison with Existing Internal Articles

The present findings extend and mechanistically refine prior discussions of FABP4 inhibition in atherosclerosis research. For example, the article "Targeting FABP4: BMS 309403 at the Forefront of Atherosclerosis Research" provided a strategic overview of leveraging BMS 309403 to modulate the CaN/FoxO1/FABP4 pathway, but the current paper delivers direct in vivo and ex vivo evidence for this pathway’s centrality. Similarly, "Targeting the CaN/FoxO1/FABP4 Pathway to Prevent Foam Cell Formation in Atherosclerosis" previously highlighted the pathway’s relevance, yet the present study offers comprehensive experimental confirmation and quantifies the protective impact of pharmacological inhibition at each step. Collectively, these resources converge on the emerging consensus that selective FABP4 inhibition—such as with BMS 309403—serves as a robust tool for dissecting lipid metabolism and inflammation in cardiovascular disease models.

Limitations and Transferability

While the study's use of a SERCA2 mutant mouse model enables precise mechanistic dissection, the heterozygous knock-in design may not fully recapitulate the complexity of human atherosclerosis, where multiple genetic and environmental factors converge. The translational relevance of targeting the CaN/FoxO1/FABP4 pathway in human disease contexts remains to be validated, especially given interspecies differences in macrophage biology and lipid metabolism. Additionally, long-term effects and safety of chronic FABP4 inhibition—beyond the scope of this study—require further investigation. These caveats notwithstanding, the study provides a strong foundation for further research into FABP4 targeting as a strategy for metabolic and cardiovascular disorders.

Protocol Parameters

• Pharmacological inhibition of FABP4: BMS 309403 administered in cell-based assays at working concentrations of 1–25 μM; stock solutions are typically prepared in DMSO or ethanol and stored at −20°C (product information).
• Genetic interventions: Partial deficiency of FABP4 achieved through heterozygous knockout in mouse models.
• Calcineurin and FoxO1 inhibition: CsA and AS1842856 used in vitro and in vivo to block upstream nodes of the pathway, as described in the reference study.
• Foam cell quantification: Oil red O staining and quantification of cholesteryl esters for macrophage lipid accumulation assessment.

Research Support Resources

Researchers seeking to replicate or extend these findings can utilize BMS 309403 (SKU B7794), a potent and selective FABP4 inhibitor, for experimental interrogation of the CaN/FoxO1/FABP4 pathway in atherosclerosis and type 2 diabetes models. BMS 309403 is available as a solid compound, soluble in DMSO or ethanol, and is suitable for both in vitro and in vivo applications as outlined above. For additional protocol details or application notes, refer to the product information from APExBIO and consult the cited primary literature.